[1] CENTER M M, JEMAL A, LORTET-TIEULENT J, et al.  International variation in prostate cancer incidence and mortality rates[J]. Europeam Urology, 2012, 61(6): 1079-1092.   doi: 10.1016/j.eururo.2012.02.054
[2] PLONIS J, BOKUMS K, CAUCE V, et al.  Prostate cancer trends in latvia during 1990—2012: Incidence, prevalence, mortality, and survival rates[J]. Medicina (Kaunas), 2014, 50(6): 313-317.   doi: 10.1016/j.medici.2014.11.002
[3] SIM H G, CHENG C W.  Changing demography of prostate cancer in Asia[J]. European Journal of Cancer, 2005, 41(6): 834-845.   doi: 10.1016/j.ejca.2004.12.033
[4] HALPERN J A, SEDRAKYAN A, HSU W C, et al.  Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer[J]. Cancer, 2016, 122(16): 2496-2504.   doi: 10.1002/cncr.30101
[5] WALLIS C J, MAHAR A, CHEUNG P, et al.  New rates of interventions to manage complications of modern prostate cancer treatment in older men[J]. European Urology, 2016, 69(5): 933-941.   doi: 10.1016/j.eururo.2015.10.043
[6] LUO X M, NIU L Z, CHEN J B, et al.  Advances in cryoablation for pancreatic cancer[J]. World Journal of Gastroenterology, 2016, 22(2): 790-800.   doi: 10.3748/wjg.v22.i2.790
[7] BAUST J G, GAGE A A, BJERKLUND J T E, et al.  Mechanisms of cryoablation: Clinical consequences on malignant tumors[J]. Cryobiology, 2014, 68(1): 1-11.   doi: 10.1016/j.cryobiol.2013.11.001
[8] MALAVAUD B.  Management of loco-regional recurrence after definitive treatment: Cryoablation[J]. European Urology Supplements, 2018, 17(1): 48-50.   doi: 10.1016/S1569-9056(18)30031-9
[9] LI Y H, ELSHAFEI A, AGARWAL G, et al.  Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: Initial results from the cryo on-line data registry[J]. Prostate, 2015, 75(1): 1-7.   doi: 10.1002/pros.22881
[10] ELLIS D S.  Cryosurgery as primary treatment for localized prostate cancer: A community hospital experience[J]. Urology, 2002, 60(2A): 34-39.
[11] LIAN H B, GUO H Q, GAN W D, et al.  Cryosurgery as primary treatment for localized prostate cancer[J]. International Urology and Nephrology, 2011, 43(4): 1089-1094.   doi: 10.1007/s11255-011-9952-7
[12] KIMURA M, DONATUCCI C F, TSIVIAN M, et al.  On-demand use of erectile aids in men with preoperative erectile dysfunction treated by whole gland prostate cryoablation[J]. International Journal of Impotence Research, 2011, 23(2): 49-55.   doi: 10.1038/ijir.2011.3
[13] ZHERDEV A A, TSIGANOV D I, PUSHKAREV A V, et al.  Cryoprobe and urethral warming system heat transfer: Ultrasound gel phantom study[J]. Journal of Enhanced Heat Transfer, 2018, 25(2): 97-108.   doi: 10.1615/JEnhHeatTransf.2018026373
[14]

SHEHATA S, HARBOR P. Apparatus and method for the controlled hydrodistention of the urinary bladder: US8167870[P]. 2012.

[15]

RABIN Y, JULIAN T B, WOLMARK N. Method and apparatus for heating during cryosurgery: US5899897[P]. 2002.

[16] PERROTTE P, LITWIN M S, MCGUIRE E J, et al.  Quality of life after salvage cryotherapy: The impact of treatment parameters[J]. Journal of Urology, 1999, 162(2): 398-402.   doi: 10.1016/S0022-5347(05)68569-2
[17] RAMAJAYAM K K, KUMAR A.  A novel approach to improve the efficacy of tumor ablation during cryosurgery[J]. Cryobiology, 2013, 67(2): 201-213.   doi: 10.1016/j.cryobiol.2013.06.013
[18] PENNES H H.  Analysis of tissue and arterial blood temperatures in the resting human forearm[J]. Journal of Applied Physiology, 1948, 1(2): 93-122.   doi: 10.1152/jappl.1948.1.2.93
[19] SABEL M S, SU G, GRIFFITH K A, et al.  Rate of freeze alters the immunologic response after cryoablation of breast cancer[J]. Annual Surgery Oncology, 2010, 17(4): 1187-1193.   doi: 10.1245/s10434-009-0846-1
[20] PADILHA M M, STEPHEN JONES J, STREATOR SMITH K, et al.  Prediction of prostate cancer to urethra distance by a pretreatment nomogram: Urethral thermoprotection implication in cryoablation[J]. Prostate Cancer Prostatic Discussion, 2013, 16(4): 372-375.   doi: 10.1038/pcan.2013.32
[21] LEIBOVICH B C, BLUTE M L, BOSTWICK D G, et al.  Proximity of prostate cancer to the urethra: Implications for minimally invasive ablativet[J]. Urology, 2000, 56(5): 726-729.   doi: 10.1016/S0090-4295(00)00792-5
[22] OSADA S, IMAI H, YAWATA K, et al.  Growth inhibition of unresectable tumors induced by hepatic cryoablation: Report of two cases[J]. Hepatogastroenterology, 2008, 55(81): 231-234.